What Is Normal Blood Sugar for Type 2 Diabetes?

Learn what blood sugar numbers to aim for with type 2 diabetes, from daily readings to A1C goals and when targets may need adjusting.

For most people with type 2 diabetes, the widely recommended targets are a fasting blood sugar under 130 mg/dL, post-meal readings under roughly 180 mg/dL, and an HbA1c below 7%. But those numbers are starting points, not universal rules. Major medical organizations disagree on the ideal HbA1c target, your doctor may set yours higher or lower based on your age and health, and newer metrics like “time in range” are reshaping how clinicians think about glucose control altogether.

The Standard Targets and Why Organizations Disagree

The American Diabetes Association and the European Association for the Study of Diabetes generally recommend an HbA1c of 7% or below for most adults with type 2 diabetes. The American Association of Clinical Endocrinology sets a tighter goal of 6.5% or below. Meanwhile, the American College of Physicians has recommended that clinicians aim for an HbA1c between 7% and 8% for most patients, arguing that pushing below 7% in many people adds medication burden without clear benefit.

That spread between 6.5% and 8% is not sloppiness. It reflects genuine disagreement about how aggressively to treat glucose in different situations. Clinical trials in older patients with established type 2 diabetes and existing cardiovascular disease did not show clear heart-related benefits from pushing HbA1c very low, and some trials raised concerns about increased hypoglycemia when targets were set too tight. The practical result is that your personal target depends on a conversation with your doctor, not a single universal number.

What Makes One Person’s Target Different From Another’s

The case for individualized targets rests on a straightforward trade-off: tighter glucose control reduces the risk of diabetes complications, but the medications and effort required to achieve it carry their own risks. Younger people with a recent diagnosis, no cardiovascular disease, and decades of life ahead generally benefit from aiming for near-normal blood sugar, because keeping glucose low early can prevent complications from accumulating over time. Older adults with long-standing diabetes, existing heart disease, or multiple other health conditions are often given a more relaxed target to avoid dangerous lows.

A multinational survey of people with type 2 diabetes found that the average individualized HbA1c goal set by physicians was about 6.8%, and only around 39% of patients were actually meeting their personal target. That gap is worth knowing about. If you are not meeting your own target, you are in the majority, and it is worth discussing medication adjustments rather than assuming your numbers are fine because they fall within some broad “normal” range you read online.

How Blood Sugar Moves Through the Day

A single HbA1c number tells you where your average glucose has been over roughly three months, but it says nothing about the daily roller coaster. In type 2 diabetes, blood sugar rises after meals more sharply and stays elevated longer than it does in people without the condition. Research comparing post-meal glucose metabolism in people with and without type 2 diabetes has shown that the spike happens primarily because the liver keeps releasing glucose even after a meal, rather than because tissues fail to take glucose in. The liver essentially does not get the message that there is already plenty of glucose circulating.

How high post-meal readings climb matters for long-term outcomes. One study looking at optimal cutoff values for post-meal glucose found that readings around 160 mg/dL by early afternoon were a reasonable marker for adequate overall control, while readings above 200 mg/dL by late morning suggested the person was off target. These are rough benchmarks, not rigid lines, but they give you a practical sense of where after-meal glucose ideally lands.

The Dawn Phenomenon

Many people with type 2 diabetes notice their fasting blood sugar is stubbornly high in the morning, sometimes higher than it was at bedtime. This is the dawn phenomenon, and it is driven by hormones. In the early morning hours, the body releases cortisol, growth hormone, and other counterregulatory hormones that prompt the liver to produce more glucose and reduce how well insulin works in muscle and liver tissue. In people without diabetes, the pancreas compensates by ramping up insulin production. In type 2 diabetes, that compensation is inadequate, so blood sugar drifts upward between roughly 4 a.m. and breakfast.

Research has confirmed that growth hormone plays a leading role, impairing insulin’s ability to suppress liver glucose output. The dawn phenomenon is not a sign that something new is wrong; it is a predictable feature of the condition. If your morning numbers are consistently higher than your bedtime readings, mention it to your doctor. Medication timing adjustments or a change in evening snacking habits can often help.

Time in Range as a Newer Way to Think About Control

HbA1c has been the standard yardstick for decades, but continuous glucose monitors have introduced a more granular metric: time in range, or the percentage of the day your glucose stays between 70 and 180 mg/dL. The general target recommended by international consensus is to spend at least 70% of the day in that window, with less than 25% of the day above 180 mg/dL and less than 4% below 70 mg/dL.

Research interest in time in range for type 2 diabetes has grown rapidly. A review found 45 randomized controlled trials involving people with type 2 diabetes that used time in range as either a primary or secondary outcome. Why does this metric matter beyond the traditional HbA1c? Because two people can have the same HbA1c while experiencing very different daily glucose patterns. One person’s glucose might hover steadily around 150 mg/dL; another’s might swing from 70 to 250 throughout the day, averaging out to the same A1c. Time in range captures that difference.

There is evidence that spending more time in range correlates with better health outcomes. A study in people with type 2 diabetes found that for every 10% increase in time spent between 70 and 180 mg/dL, the odds of having albuminuria (an early marker of kidney damage) dropped by about 6%. That connection held even after accounting for differences in HbA1c, which suggests time in range is picking up information about glucose control that HbA1c misses.

Why Swings in Blood Sugar Matter, Not Just the Average

Glucose variability, meaning how much your blood sugar bounces around from hour to hour and day to day, is increasingly recognized as a risk factor in its own right. Clinical studies and meta-analyses have found that greater glucose variability is linked to cardiovascular complications and death independently of HbA1c level. In other words, wild swings in glucose appear to cause additional damage to blood vessels beyond what a high average alone would predict.

A meta-analysis focused on cardiovascular risk factors in type 2 diabetes concluded that minimizing glucose variability could improve insulin resistance and reduce arterial wall thickening, both of which lower the risk of heart disease. This is one of the reasons continuous glucose monitors are gaining traction even for people with type 2 diabetes who are not on insulin. Seeing the daily pattern, rather than relying on occasional finger sticks and a quarterly lab draw, lets you identify and address spikes and dips you would otherwise never know about.

Long-Term Outcomes Linked to Glucose Levels

The relationship between HbA1c and complications is not a sharp cliff but a gradual slope. The landmark UK Prospective Diabetes Study found that each 1% reduction in HbA1c was associated with a 21% lower risk of any diabetes-related endpoint, a 14% lower risk of heart attack, and a 37% lower risk of microvascular complications like eye and kidney disease. That study found no clear threshold below which further reductions stopped helping.

Later analyses refined this picture. A study of patients in the ADVANCE trial identified apparent thresholds: below an HbA1c of about 7%, the risk of major cardiovascular events and death did not continue to drop significantly, though microvascular risk kept declining down to about 6.5%. Above those thresholds, each additional 1% increase in HbA1c was associated with roughly a 38–40% increase in the risk of cardiovascular events, microvascular events, and death.

There is also growing evidence for a “legacy effect,” where early glucose control pays dividends years down the line. A large UK study found that the risk of microvascular disease climbed progressively with rising HbA1c, with those whose HbA1c reached above about 9.6% facing roughly 70% higher risk compared to the reference group. The takeaway is that getting glucose under control early matters more than perfecting it later.

How Different Medications Shape Your Daily Glucose Pattern

Not all diabetes medications produce the same daily glucose profile, even when they lower HbA1c by a similar amount. This is where glucose variability becomes a practical consideration rather than an academic one. A network meta-analysis of randomized controlled trials compared the effects of major drug classes on glucose swings measured by Mean Amplitude of Glycemic Excursions (a standard measure of how wildly glucose bounces). GLP-1 receptor agonists produced the smoothest profile, followed by DPP-4 inhibitors and thiazolidinediones.

Sulfonylureas, an older and cheaper drug class, deserve special mention. While effective at lowering HbA1c, they tend to create wider glucose swings than other medications. A study using continuous glucose monitoring found that even in patients whose overall control looked good by HbA1c standards, sulfonylurea use was linked to significantly greater glucose variability, and high-dose sulfonylurea use was associated with more time spent in a dangerously low glucose range below 54 mg/dL. A patient’s HbA1c could look fine while their daily glucose profile includes concerning lows that a standard lab test never catches.

SGLT2 inhibitors, by contrast, showed favorable glucose control and relatively low variability in a study using flash glucose monitoring, with lower standard deviation and coefficient of variation compared to other drug classes. If your medications keep your average in a reasonable range but you are experiencing frequent lows or erratic highs, the class of medication may be part of the story.

The Danger of Going Too Low

Conversations about “normal” blood sugar in type 2 diabetes often focus on highs, but lows can be more immediately dangerous. Hypoglycemia, generally defined as glucose below 70 mg/dL, triggers symptoms like shakiness, sweating, confusion, and irritability. If it drops further, particularly below 54 mg/dL, it can cause seizures, loss of consciousness, and cardiac events.

There is a particularly insidious pattern called hypoglycemia unawareness, where repeated low episodes blunt the body’s warning signals. The normal hormonal and symptom responses that alert you to falling blood sugar become muted, so dangerous lows can occur without the person feeling anything wrong. This raises the risk of severe hypoglycemia, which is associated with cardiovascular events and cognitive impairment over time. This is one of the key reasons clinicians are cautious about setting very aggressive glucose targets, particularly in people who are on insulin or sulfonylureas.

Exercise and Meal Composition

Two of the biggest levers you have for controlling blood sugar day to day are physical activity and what you eat, with effects that show up in controlled research.

On the exercise side, even a single session of high-intensity interval training reduced the proportion of the day spent with blood sugar above 180 mg/dL from about 15% to about 5% in people with type 2 diabetes, and total post-meal glucose exposure dropped by roughly a third on exercise days. Longer-term programs show compounding benefits: a two-week program of brief high-intensity exercise reduced average blood glucose by about 13% measured two to three days after the last session. You do not necessarily need long gym sessions. Short, intense bursts appear to be particularly effective at pulling down post-meal glucose.

Meal composition also matters in straightforward ways. When people ate carbohydrates with added protein, blood sugar at the one-hour mark was significantly lower than when they ate the same carbohydrates alone. A controlled feeding study confirmed this, finding that adding a substantial amount of protein to a carbohydrate-rich meal lowered the overall glycemic response, while adding fat or fiber in the amounts tested did not have a significant effect. The practical translation: pairing your carbohydrate-heavy foods with a good protein source is one of the simplest ways to blunt a post-meal spike.

Targets for Older Adults and Those With Frailty

For older adults, especially those who are frail or managing several other health conditions, the standard targets often do not apply. Diabetes guidelines generally recommend relaxing HbA1c goals to around 7.5–8.5% in this population, depending on the person’s overall health and life expectancy. The reasoning is practical: older adults are more prone to hypoglycemia and more vulnerable to its consequences, which include falls, fractures, hospitalization, cardiovascular events, and death.

If you are caring for an older parent or grandparent with type 2 diabetes, a fasting glucose of 150 mg/dL might be perfectly appropriate for them, even though it would be above the standard target for a younger person. The goal shifts from preventing long-term complications (which take years to develop) toward preventing the immediate harm of dangerously low blood sugar and preserving quality of life.

When HbA1c Can Mislead

HbA1c measures how much glucose has attached to hemoglobin in your red blood cells over their roughly three-month lifespan. Anything that changes how red blood cells behave or how long they last can throw the number off. Certain hemoglobin variants, which are relatively common in some populations, can cause HbA1c assays to read inaccurately depending on the testing method used. Conditions that affect red blood cell turnover, such as iron deficiency anemia, chronic kidney disease, or recent blood transfusions, can also shift HbA1c results up or down in ways that do not reflect actual glucose levels.

This is another reason continuous glucose monitoring or regular finger-stick testing adds value. If your HbA1c does not match what your daily readings are telling you, the discrepancy itself is information worth discussing with your doctor.

What Remission Looks Like

A growing number of people with type 2 diabetes are achieving remission, typically through significant weight loss from dietary changes, exercise, or bariatric surgery. An international expert consensus defined remission as an HbA1c below 6.5% measured at least three months after stopping all glucose-lowering medications. The word “remission” was chosen deliberately over “reversal” or “cure” because the underlying tendency toward insulin resistance does not fully disappear, and blood sugar can climb again if the conditions that drove it are restored.

Interestingly, a systematic review of how remission has been defined across research studies found considerable inconsistency. The most commonly used threshold was actually an HbA1c below 6.0%, stricter than the consensus definition, though the field has been moving toward standardization around the 6.5% cutoff. If someone tells you they have “reversed” their diabetes, what that usually means in clinical terms is that they have achieved and are maintaining an HbA1c below 6.5% without medication, which is a remarkable achievement but not quite the same as no longer having the condition.